This clinical trial evaluates how well a new smartphone-based application (app), called Prostate Cancer Genius App (PCGA), works in providing prostate cancer education and promoting home-based prostate-specific antigen (PSA) screening in African American men compared to an existing app, called Prevention Taskforce App (PTFA). Prostate cancer is the most diagnosed cancer in African American men and the second leading cause of cancer-related death. The PSA test is an early detection screening tool for prostate cancer, and greater PSA screening uptake among African Americans may eliminate disparities in this disease. However, knowledge about prostate cancer and screening benefits and risks and uptake of PSA screening remains low among African American men. Developing a prostate cancer prevention app that is designed for minority populations and improves prostate cancer knowledge as well as provide step-by-step navigation of completing a home-based PSA test may help to eliminate barriers and optimize the delivery of equitable preventive healthcare for African American men.
Additional locations may be listed on ClinicalTrials.gov for NCT05331638.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVE:
I. Evaluate the preliminary efficacy of a prostate cancer prevention app on prostate cancer knowledge.
SECONDARY OBJECTIVES:
I. Derive preliminary estimates of the effects of a prostate cancer prevention app on PSA test readiness.
II. Explore the perceived engagement, accessibility, and acceptability of a prostate cancer prevention app.
EXPLORATORY OBJECTIVE:
I. Derive preliminary estimates of the effects of PCGA on PSA screening test completion rates and identify mechanisms of screening adherence.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I: Participants use the PTFA smartphone app to complete assessments once weekly (QW) for 4 weeks and receive on-demand access to general prostate cancer information and recommendations for up to 30 days. Participants also receive an educational brochure and the option to order one free home-based PSA screening test on study. Participants who opt for home-based PSA testing undergo a finger stick blood sample collection and recieve instructions for follow-up care for elevated or abnormal PSA results on study.
ARM II: Participants use the PCGA smartphone app to complete assessments QW for 4 weeks and receive on-demand access to general and tailored prostate cancer information and recommendations for up to 30 days. Participants receive on-demand access and app notifications to complete learning modules, watch testimonial videos from cancer survivors, and talk with prostate cancer survivor peer coaches, as well as tailored risk and efficacy messaging QW on study. Participants also receive the option to order one free home-based PSA screening test with tailored navigation on study. Participants who opt for home-based PSA testing undergo a finger stick blood sample collection and receive instructions for follow-up care for elevated or abnormal PSA results on study.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationUniversity of Oklahoma Health Sciences Center
Principal InvestigatorAdam C. Alexander
